Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000820871 | SCV000961604 | uncertain significance | Severe combined immunodeficiency due to IKK2 deficiency | 2025-01-06 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 77 of the IKBKB protein (p.Arg77Gln). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with IKBKB-related conditions. ClinVar contains an entry for this variant (Variation ID: 663077). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Genetics and Molecular Pathology, |
RCV000820871 | SCV004175591 | uncertain significance | Severe combined immunodeficiency due to IKK2 deficiency | 2022-04-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004986636 | SCV005598745 | uncertain significance | Inborn genetic diseases | 2024-11-11 | criteria provided, single submitter | clinical testing | The c.230G>A (p.R77Q) alteration is located in exon 4 (coding exon 3) of the IKBKB gene. This alteration results from a G to A substitution at nucleotide position 230, causing the arginine (R) at amino acid position 77 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |